Volvo ES90 review: Forward-looking tech in a trad saloon package May 9, 2026 Volvo is back in the luxury saloon game, with the fully electric ES90 offering an alternative to its range of SUVs. John Redfern discovers how it measures up. During the past decade, Volvo has made SUVs central to its model lineup. It makes the new ES90 something of an outlier – and a reminder of [...]
Janus Henderson Group plc Reports First Quarter 2026 Results May 8, 2026 Solid long-term investment performance, with 66%, 67%, and 68% of assets under management (“AUM”) outperforming relevant benchmarks on a three-, five-, and 10-year basis, respectively, as of March 31, 2026 AUM of US$480 billion as of March 31, 2026, an increase of 29% year over year First quarter 2026 net inflows of US$2.9 billion compared to breakeven net flows in fourth quarter 2025 First quarter 2026 diluted EPS of US$0.59 and adjusted diluted EPS of US$0.90
Bulb’s chances are bright under Magic Man Moreira May 8, 2026 REGULAR Hong Kong racegoers will need to wait until the finale at Sha Tin for the feature race on the card – the six-furlong Class Two Sai Wan Shan Handicap (10.45am). The contest promises to be a mouth-watering spectacle, featuring some of the best handicap sprinters in town up against a couple of potential future [...]
Porsche Cayenne Electric review: luxury SUV is the most powerful Porsche ever May 8, 2026 The new Porsche Cayenne Electric Turbo is the model that will grab all the headlines. With up to 1,156hp, it’s the most powerful Porsche road car ever. At 2.5 seconds to 62mph, it accelerates as quickly as the new Porsche 911 Turbo Swe drove recently. Yet this is not a sports car, but a five-metre-long [...]
New ‘360 degree video’ of David Attenborough hits central London May 8, 2026 A new immersive installation at Outernet – that mad box of screens outside Tottenham Court Road station – will celebrate the life of Sir David Attenborough as he turns 100. The five-minute “360 degree video” launches today, with fans able to simply walk in and gawp at animations and real-world footage of David Attenborough. Entitled [...]
Patrick Cox: Tax the rich, bring back the guillotine! May 8, 2026 Iconic 90s shoe designer Patrick Cox, and soon-to-be Cordwainer, takes us on a trip down memory lane in this week's Square Mile and Me.
AngloGold Ashanti Q1 31 March 2026 Earnings Release and Dividend Declaration May 8, 2026 AngloGold Ashanti delivers record free cash flow* of $1.2bn and EBITDA*(4) of $2.3bn • Gold production(1)(2) +1% • Net cash*(4) of $868m • Q1 2026 interim dividend of $585m, or 116 cps • Proposed $2.0bn share repurchase programme announced
In defence of Bristol Bears CEO Tom Tainton’s rugby marketing comments May 8, 2026 “At Bristol Bears, we don’t call ourselves a rugby club. We are a marketing agency that plays rugby. Yes, our players have to be competent and able to deliver on the field, but if they are not bringing any value off the field, that genuinely factors into our recruitment conversations.” Those were the words of [...]
Drill baby brill: Why the UK must develop it’s North Sea oil fields May 8, 2026 In light of international crises like the war in Iran and the resulting energy price spikes, the UK’s fundamental energy vulnerability – its dependence on a volatile international market – can be solved by immediately approving further drilling in the North Sea, says Brandon Lewis Moments of crisis have a clarifying power that peacetime politics [...]
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate